Abstract
Background and Objective: Alzheimer's disease (AD) is arguably the largest healthcare issue of our time. AD is thought to be principally the result of an inter-play between the β-amyloid peptide and Tau, and it is driven by several genetic and environmental risk factors. Recent studies have shown that small non-protein-coding microRNA (miRNA) and the associated post-transcriptional gene regulation are important regulators of many neurodegenerative diseases, including AD. We reviewed recent studies identifying various miRNA dysregulated in AD. These miRNAs could play a significant role in the pathophysiology of AD, in both β-amyloid peptide and Tau toxicity.
Conclusion: The identification of dysregulated miRNAs pattern can serve as specific AD biomarkers which may provide the basis for new and effective diagnostic approach. In addition, these miRNAs may represent new targets for pharmaceutical development.
Keywords: Alzheimer disease, microRNA, β-amyloid, Tauopathy, biomarker, treatment.
CNS & Neurological Disorders - Drug Targets
Title:MicroRNA Dysregulation in Alzheimer's Disease
Volume: 16 Issue: 9
Author(s): Manish Putteeraj, Yahaya Mohamad Fairuz and Seong Lin Teoh*
Affiliation:
- Department of Anatomy, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur,Malaysia
Keywords: Alzheimer disease, microRNA, β-amyloid, Tauopathy, biomarker, treatment.
Abstract: Background and Objective: Alzheimer's disease (AD) is arguably the largest healthcare issue of our time. AD is thought to be principally the result of an inter-play between the β-amyloid peptide and Tau, and it is driven by several genetic and environmental risk factors. Recent studies have shown that small non-protein-coding microRNA (miRNA) and the associated post-transcriptional gene regulation are important regulators of many neurodegenerative diseases, including AD. We reviewed recent studies identifying various miRNA dysregulated in AD. These miRNAs could play a significant role in the pathophysiology of AD, in both β-amyloid peptide and Tau toxicity.
Conclusion: The identification of dysregulated miRNAs pattern can serve as specific AD biomarkers which may provide the basis for new and effective diagnostic approach. In addition, these miRNAs may represent new targets for pharmaceutical development.
Export Options
About this article
Cite this article as:
Putteeraj Manish , Fairuz Mohamad Yahaya and Teoh Lin Seong *, MicroRNA Dysregulation in Alzheimer's Disease, CNS & Neurological Disorders - Drug Targets 2017; 16 (9) . https://dx.doi.org/10.2174/1871527316666170807142311
DOI https://dx.doi.org/10.2174/1871527316666170807142311 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems
Current Pharmaceutical Design Subject Index To Volume 6
Current Molecular Medicine Voltage-Gated Sodium Channel Blockers: Synthesis of Mexiletine Analogues and Homologues
Current Medicinal Chemistry Protective Effects of Caffeic Acid and the Alzheimer's Brain: An Update
Mini-Reviews in Medicinal Chemistry Is Human Immunodeficiency Virus-Mediated Dementia an Autophagic Defect that Leads to Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Protein Glycation: An Old Villain is Shedding Secrets
Combinatorial Chemistry & High Throughput Screening MAPKs as Mediators of Cell Fate Determination: an Approach to Neurodegenerative Diseases
Current Medicinal Chemistry Autophagy in the Central Nervous System: Implications for Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Healthy Gut, Healthy Brain: The Gut Microbiome in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Pathophysiology of Neurodegeneration in Familial Amyotrophic Lateral Sclerosis
Current Molecular Medicine Calpains as a Target for Therapy of Neurodegenerative Diseases: Putative Role of Lithium
Current Drug Metabolism Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets Tau Therapeutic Strategies for the Treatment of Alzheimers Disease
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Regenerative Medicine in Neurological Diseases)
Recent Patents on Regenerative Medicine Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Targeting Neurotrophic/Growth Factor Expression and Signaling for Antidepressant Drug Development
CNS & Neurological Disorders - Drug Targets Programmed Axon Death, Synaptic Dysfunction and the Ubiquitin Proteasome System
Current Drug Targets - CNS & Neurological Disorders The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Mitochondria-Targeted Antioxidant Peptides
Current Pharmaceutical Design